

# Rajat Kumar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4687196/publications.pdf>

Version: 2024-02-01

48  
papers

476  
citations

1051969

10  
h-index

843174

20  
g-index

48  
all docs

48  
docs citations

48  
times ranked

726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 50.e1-50.e8.	0.6	11
2	Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma. <i>European Journal of Haematology</i> , 2022, 108, 430-436.	1.1	2
3	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 265.e1-265.e9.	0.6	6
4	The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. <i>EJHaem</i> , 2022, 3, 873-884.	0.4	2
5	Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	2
6	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 60-69.	1.3	26
7	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. <i>Bone Marrow Transplantation</i> , 2021, 56, 689-691.	1.3	1
8	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2021, 106, 32-39.	1.1	16
9	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , 2021, 106, 158-164.	1.1	2
10	Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	3
11	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1311-1319.	0.8	2
12	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1908-1918.	1.3	10
13	Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. <i>Leukemia and Lymphoma</i> , 2021, 62, 2193-2201.	0.6	5
14	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 428.e1-428.e9.	0.6	11
15	Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2471-2476.	1.3	5
16	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. <i>European Journal of Haematology</i> , 2021, 107, 517-528.	1.1	2
17	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 600.e1-600.e8.	0.6	5
18	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 3373-3383.	0.6	12

#	ARTICLE	IF	CITATIONS
19	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. <i>European Journal of Haematology</i> , 2021, 106, 508-519.	1.1	1
20	Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. <i>Blood</i> , 2021, 138, 3905-3905.	0.6	0
21	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	0
22	Eltrombopag: Role in Cytopenias Following Hematopoietic Stem Cell Transplantation. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 238-245.	0.3	6
23	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 104, 36-45.	1.1	7
24	Graft-versus-Host Disease-Free Relapse-Free Survival Definition for Patients with Nonmalignant Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 428.	2.0	2
25	Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival. <i>European Journal of Haematology</i> , 2020, 104, 116-124.	1.1	5
26	Impact of Covid-19 on Hematological Practice: Challenges and Opportunities. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 603-604.	0.3	2
27	Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1995-2000.	2.0	2
28	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 3198-3208.	0.6	9
29	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1511-1519.	2.0	6
30	Transitioning to a New Normal in the Post-COVID Era. <i>Current Oncology Reports</i> , 2020, 22, 73.	1.8	10
31	Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 105, 24-29.	1.1	5
32	COVID-19 Testing in Patients with Cancer: Does One Size Fit All?. <i>Clinical Cancer Research</i> , 2020, 26, 4737-4742.	3.2	23
33	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , 2020, 55, 1773-1783.	1.3	35
34	Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: Updated Results from a Systematic Review. <i>Blood</i> , 2020, 136, 11-12.	0.6	0
35	Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease. <i>European Journal of Haematology</i> , 2019, 103, 519-522.	1.1	2
36	Impressive Graft-versus-Host Disease-Free, Relapse-Free Survival in Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and a Combination of Antithymocyte Globulin and Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e352-e353.	2.0	3

#	ARTICLE	IF	CITATIONS
37	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. European Journal of Haematology, 2019, 103, 597-606.	1.1	9
38	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. European Journal of Haematology, 2019, 103, 510-518.	1.1	19
39	Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. European Journal of Haematology, 2019, 103, 483-490.	1.1	10
40	Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. European Journal of Haematology, 2019, 102, 486-493.	1.1	32
41	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. Clinical Hematology International, 2019, 1, 105-113.	0.7	18
42	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. Blood, 2019, 134, 3344-3344.	0.6	0
43	The 17-Gene Leukemic Stemness Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Blood, 2019, 134, 3299-3299.	0.6	0
44	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. Blood, 2019, 134, 4590-4590.	0.6	0
45	No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. Blood, 2019, 134, 4514-4514.	0.6	0
46	Bilateral adrenal hemorrhage as a manifestation of extramedullary hematopoiesis in a patient with primary myelofibrosis. Annals of Hematology, 2018, 97, 2011-2012.	0.8	3
47	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, 2259-2264.	2.0	66
48	Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. British Journal of Haematology, 2016, 174, 88-101.	1.2	78